New immunotherapy combo may let older colorectal cancer patients skip surgery

NCT ID NCT06205836

Recruiting now Disease control Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether immunotherapy drugs (cemiplimab alone or with fianlimab) can shrink or eliminate tumors in older patients (70+) or those unfit for surgery with a specific genetic type of colorectal cancer (MSI-H). The goal is to avoid surgery if the cancer disappears completely on scans and endoscopy. Participants will be monitored for 24 months, and the study tracks both how well the treatment works and any serious side effects.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

adenocarcinoma carcinoma colorectal cancer colorectal neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

COLORECTAL CANCER

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Johns Hopkins SKCCC
RECRUITING

Baltimore, Maryland, 21231, United States

Contact Phone: •••-•••-•••• Email: •••••@•••••

Contact